Comparative antibacterial activity of the new oral cephalosporin BMY-28100.

The in vitro activity of BMY-28100 was compared with that of four other oral cephalosporins against gram-positive cocci, Branhamella catarrhalis and Haemophilus influenzae. BMY-28100 showed 5-20 times better activity against staphylococci and streptococci. Methicillin-resistant staphylococci and enterococci were resistant to the drug. Branhamella catarrhalis and Haemophilus influenzae strains were moderately susceptible. Time-kill curve studies showed BMY-28100 to be equally as active as benzylpenicillin, amoxycillin, flucloxacillin and cefaclor. By virtue of its in vitro spectrum, BMY-28100 can be considered a potentially useful agent for treatment of respiratory tract infections.